This Article Abstract Full Text (PDF) All Versions of this Article: 107/20/2601    most recent 01.CIR.0000066910.02844.D0v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Day, S. M. Articles by Fay, W. P. Search for Related Content PubMed PubMed Citation Articles by Day, S. M. Articles by Fay, W. P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYSTEINE IRON IRON DEXTRAN NITRIC OXIDE Related Collections Animal models of human disease Arterial thrombosis Oxidant stress

(Circulation. 2003;107:2601.)
© 2003 American Heart Association, Inc.

Basic Science Reports

Chronic Iron Administration Increases Vascular Oxidative Stress and Accelerates Arterial Thrombosis

Sharlene M. Day, MD; Damon Duquaine, BS; Lakshmi V. Mundada, MS; Rekha G. Menon, MD; Bobby V. Khan, MD, PhD; Sanjay Rajagopalan, MD; William P. Fay, MD

From the University of Michigan Medical School, Division of Cardiology, Ann Arbor (S.M.D., D.D., L.V.M., S.R., W.P.F.); and Emory University School of Medicine, Division of Cardiology, Atlanta, Ga (R.G.M., B.V.K.).

Correspondence to Sharlene M. Day, MD, University of Michigan Medical Center, 7301 MSRB III, 1150 W Medical Center Dr, Ann Arbor, MI 48109-0644. E-mail sday{at}umich.edu

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Iron overload has been implicated in the pathogenesis of ischemic cardiovascular events. However, the effects of iron excess on vascular function and the thrombotic response to vascular injury are not well understood.

Methods and Results— We examined the effects of chronic iron dextran administration (15 mg over 6 weeks) on thrombosis, systemic and vascular oxidative stress, and endothelium-dependent vascular reactivity in mice. Thrombus generation after photochemical carotid artery injury was accelerated in iron-loaded mice (mean time to occlusive thrombosis, 20.4±8.5 minutes; n=10) compared with control mice (54.5±35.5 minutes, n=10, P=0.009). Iron loading had no effect on plasma clotting, vessel wall tissue factor activity, or ADP-induced platelet aggregation. Acute administration of DL-cysteine, a reactive oxygen species scavenger, completely abrogated the effects of iron loading on thrombus formation, suggesting that iron accelerated thrombosis through a pro-oxidant mechanism. Iron loading enhanced both systemic and vascular reactive oxygen species production. Endothelium-dependent vasorelaxation was impaired in iron-loaded mice, indicating reduced NO bioavailability.

Conclusions— Moderate iron loading markedly accelerates thrombus formation after arterial injury, increases vascular oxidative stress, and impairs vasoreactivity. Iron-induced vascular dysfunction may contribute to the increased incidence of ischemic cardiovascular events that have been associated with chronic iron overload.

Key Words: thrombosis • free radicals • arteries

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Although iron is essential for many physiological processes, excess iron can lead to tissue damage by promoting the generation of reactive oxygen species (ROS) through the Fenton reaction.¹ Primary iron overload occurs in patients with hereditary hemochromatosis, which is one of the most common recessive genetic disorders.² Carriers of the hemochromatosis gene can have moderate iron overload compared with age-matched normal subjects³ and have higher serum free iron levels.⁴ Secondary tissue iron overload can result from frequent blood transfusions or parenteral iron infusions.⁵ Although controversial, several lines of evidence suggest that iron excess may predispose to vascular disease. Elevated body iron stores were associated with an increased risk of myocardial infarction in a large cohort of Finnish men.⁶ Carriers of the hemochromatosis gene appear to be at increased risk of myocardial infarction and cardiovascular death, an effect synergistic with other risk factors associated with increased oxidative stress, such as hypertension and smoking.^7,8 Because iron is capable of supporting lipid peroxidation,^9,10 acceleration of atherosclerosis development has been postulated as a potential mechanism by which iron overload may increase the risk of ischemic cardiovascular events. However, animal and human studies have not found a consistent effect of iron overload on atherogenesis.^11–15

By promoting the generation of ROS, excess iron may predispose to ischemic cardiovascular events by mechanisms independent of atherosclerotic burden.¹⁶ Thrombotic arterial occlusion after plaque rupture, leading to unstable angina and myocardial infarction, constitutes the major cause of morbidity and mortality associated with coronary artery disease. Increased levels of oxidative stress have been demonstrated in patients with unstable angina,¹⁷ suggesting that ROS may contribute to plaque disruption and thrombosis.¹⁸ In vitro studies have shown that iron acutely promotes platelet reactivity¹⁹ and that iron chelation inhibits activation of tissue factor (TF).²⁰ However, the effects of chronic iron overload on arterial thrombosis are unknown.

Iron may also have deleterious effects on vascular function. Locally enhanced vascular production of ROS decreases the bioavailability of nitric oxide (NO), impairing vasorelaxation and promoting platelet adhesion and aggregation.²¹ Therefore, a dynamic interaction exists between endothelial function and thrombosis, both of which may be influenced by oxidative stress. Yet, limited data are available on the effects of chronic iron overload on ROS production within the arterial wall or on vascular function.

We conducted a series of animal experiments to test the hypotheses that iron overload contributes to the development of vascular disease by promoting thrombosis after arterial injury, by catalyzing ROS generation in the blood vessel wall, and by adversely affecting endothelium-dependent vasoreactivity. Our results support an important role of iron excess in thrombosis and vascular dysfunction that may help to explain the postulated association between elevated body iron stores and ischemic cardiovascular events.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Animals
Eight- to 10-week-old C57BL/6 male mice (Jackson Labs, Bar Harbor, Maine) were given 1.5 mg of iron dextran (Sigma Chemical Co) diluted in 0.9% NaCl by intraperitoneal injection every 3 to 5 days for a total of 10 doses over 6 weeks. Control animals received saline. Mice were fed a laboratory rodent diet (PMI Feeds Inc, Formula 5001 containing 198 ppm iron and distilled water. The University of Michigan Committee on Use and Care of Animals approved all experimental procedures.

Carotid Artery Thrombosis Model
Photochemical vascular injury was performed in an unblinded fashion as previously described.²² Where indicated, 100 mg/kg DL-cysteine hydrochloride (Sigma) in PBS or an equal volume of PBS alone was injected into the tail vein 5 minutes after initiation of injury. Occlusion time was defined as the interval from initiation of injury until a reduction in carotid blood flow to 0 mL/min persisting for 1 minute. The arterial vasculature was perfusion fixed with 10% formalin at the completion of the protocol. The carotid arteries and livers were paraffin-embedded, sectioned, and stained with hematoxylin and eosin or Prussian blue.

Coagulation and Platelet Function Assays
Blood hemoglobin concentration was measured with Drabkin’s reagent in a chromogenic assay (Sigma). Platelet counts were determined in whole blood with the use of an automated cell counter (Hemavet, CDC Technologies). An Amelung clotting apparatus (Sigma) was used to measure the prothrombin time (PT) and the activated partial thromboplastin time (aPTT). TF activity in carotid artery homogenates was measured by a previously described clotting-based assay.²³ Platelet aggregation was performed as described previously.²²

Vascular Studies
Aortic rings (4 mm) were suspended in individual organ chambers filled with PSS buffer (in mmol/L: NaCl, 99.0; KCl, 4.7; CaCl₂, 1.9; MgSO₄, 1.2; K₂HPO₄, 1.0; NaHCO₃, 25.0; and glucose, 11.1; pH 7.4) containing indomethacin (10 µmol/L), aerated continuously with 5% CO₂ in O₂ at 37°C. The vessels were preconstricted with gradual doses of L-phenylephrine (0.15 µmol/L) to reach a stable contraction plateau that approximated 40% to 50% of peak tension generated with maximal dose KCl. The rings were then exposed to graded doses of acetylcholine (1 nmol/L to 1 µmol/L), followed by nitroglycerin (1 nmol/L to 10 µmol/L). Results were reported as percent relaxation for each concentration of agonist and as ED₅₀, that is, the agonist dose at which 50% of maximal relaxation was achieved.²⁴ In situ detection of ROS formation in the vessel wall was assessed with the use of the oxidatively active fluorescent dye 2',7'-dichlorodihydrofluorescein diacetate (DCFDA, Molecular Probes). Unfixed aortic ring segments were frozen in OCT and cut into 30-µm cross sections. DCFDA (5 µmol/L) was applied to each section for 5 minutes at room temperature. Before application of DCFDA, some cross sections were pretreated for 20 minutes at 37°C with N-2-mercaptopropionyl glycine (MPG, 100 µmol/L) or catalase (350 U/mL), scavengers of hydroxyl radical and H₂O₂, respectively. Arteries were scanned with a laser confocal microscope (Biorad MRC-600) as described.²⁵

Biochemical Analyses
Serum albumin, total cholesterol, iron, and total iron-binding capacity were measured by means of chromogenic assays (Sigma). Twenty-four-hour urine samples were collected in metabolic cages. Urinary 6-keto prostaglandin F₁ and 11-dehydro thromboxane B₂, the stable metabolites of prostacyclin and thromboxane A₂ (TXA₂), respectively, were measured by ELISA (Cayman Chemical). NO production was assessed by use of a colorimetric assay for urinary nitrate/nitrite concentration (Cayman Chemical). Nonheme iron content (expressed in µg/g dry wt tissue) was measured in livers, spleens, and aortas as previously described.²⁶ Thiobarbituric acid reactive substances (TBARS) were measured with the use of a commercially available assay according to the manufacturer’s instructions (Oxi-tek, Zeptometrix Corporation). Malondialdehyde (MDA)-LDL levels were measured by ELISA,²⁷ and plasma free F₂-isoprostanes were measured by stable isotope dilution mass spectrometry.²⁸

Statistical Analyses
Thrombosis times of iron-loaded and control animals were compared by proportional hazards modeling with SAS 8.2 (SAS Institute). All other results were expressed as mean±SD and analyzed by 2-tailed Student’s t tests for unpaired data.

	Results

Top Abstract Introduction Methods Results Discussion References

 
After 6 weeks of iron loading, mice appeared healthy and weighed the same as saline-treated animals (29.9±2.0 g for each group). There was no difference in serum albumin (3.2±0.2 g/dL versus 3.0±0.3; P=0.14, n=8 per group) or total cholesterol (81±3 mg/dL versus 77±12; P=0.28, n=8 per group) between iron-loaded and control groups, suggesting adequate nutritional status and normal hepatic synthetic function. The mean heart/body weight ratio (4.18±0.20 mg/g versus 4.37±0.30; P=0.10, n=10 per group) and lung/body weight ratio (4.79±0.34 mg/g versus 4.65±0.54; P=0.51, n=10 per group) did not differ between iron-loaded and control groups, respectively.

Iron Contents and Histology
Serum and tissue iron parameters are summarized in Table 1. Livers of iron-loaded animals had normal architecture with no evidence of inflammation, necrosis, or scarring. Prussian blue staining revealed iron deposits predominantly localizing to tissue macrophages (Figure 1, A and B). Although nonheme iron content was elevated 4-fold in the aortas of iron-loaded mice, Prussian blue staining did not detect any carotid arterial iron (Figure 1, C and D). Noninjured carotid arteries appeared histologically normal by hematoxylin and eosin staining in both groups (data not shown).

View this table: [in this window] [in a new window]   TABLE 1. Serum and Tissue Iron Parameters

View larger version (149K): [in this window] [in a new window]   Figure 1. Histology of carotid arteries and livers. A, Hematoxylin and eosin stain of liver section from an iron-loaded animal. Arrow denotes a hemosiderin-laden macrophage. B, Prussian blue stain of liver from an iron-loaded animal, with arrow denoting positive staining of a Kupffer cell. C, Control, and D, iron-loaded artery stained with Prussian blue. Magnification x200; scale bar=50 µm for all.

Thrombosis Studies
Thrombus formation after photochemical carotid artery injury was accelerated in iron-loaded animals compared with control animals (Figure 2). Mean occlusion times were 20.4±8.5 minutes in the iron-loaded animals versus 54.5±35.5 minutes in the saline-treated animals (P<0.01; n=10 for each group). Occlusion occurred in <30 minutes in 9 of 10 iron-loaded mice but only in 2 of 10 control animals. We performed a series of experiments to examine potential mechanisms by which iron overload could accelerate thrombus formation. To determine whether the effects of iron were attributable to generation of ROS, the aminothiol DL-cysteine, a nonspecific ROS scavenger, was administered 5 minutes after initiation of vascular injury. DL-Cysteine caused a statistically insignificant prolongation of the mean occlusion time of control animals (to 88.0±29.9 minutes, n=5, P=0.23, Figure 2). In contrast, DL-cysteine significantly inhibited thrombus formation in the iron-loaded animals (mean occlusion time increased to 75.5±42.6 minutes, n=5, P<0.01). Administration of PBS alone had no effect on occlusion times in either group (data not shown).

View larger version (21K): [in this window] [in a new window]   Figure 2. Carotid artery thrombosis. Percentage of animals with patent arteries in each group are plotted as a function of time after initiation of photochemical injury.

The effects of iron loading on coagulation parameters and platelet function were also examined. Whole blood hemoglobin concentration, platelet counts, PT, aPTT, vessel wall TF activity, and ADP-induced platelet aggregation did not differ significantly between groups (Table 2). Production of two important mediators of platelet activation, prostacyclin and TXA₂, was assessed by measuring their respective urinary metabolites, 6-keto prostaglandin F₁ and 11-dehydro thromboxane B₂. Urinary 6-keto prostaglandin F₁ levels were significantly elevated in iron-loaded mice versus control mice (22.7±4.2 ng/mg creatinine [n=4] versus 8.8±2.0 [n=5], respectively; P=0.0003), and there was a trend toward higher 11-dehydro thromboxane B₂ levels (6.2±2.7 ng/mg creatinine [n=8] versus 4.1±2.6 [n=10]; P=0.12).

View this table: [in this window] [in a new window]   TABLE 2. Hemostatic and Coagulation Parameters

Vascular ROS Production and Systemic Oxidative Stress
The production of ROS within the arterial wall was assessed in situ by incubating aortic cross sections from iron-loaded and control mice with the oxidatively active fluorescent dye DCFDA. No ROS were detectable in cross sections (n=3 per artery) from control animals (n=3, Figure 3A). In contrast, cross sections from iron-loaded animals (n=3) demonstrated markedly increased DCFDA staining, particularly within the adventitia (Figure 3B). In some sections, ROS were also detected in the intima (Figure 3C). Catalase and MPG, scavengers of H₂O₂ and OH·, respectively, almost completely abolished this signal (Figure 3, D and E). Systemic markers of oxidative stress, including TBARS, MDA, and F₂-isoprostanes, were also significantly elevated in iron-loaded animals versus control animals (Table 3).

View larger version (29K): [in this window] [in a new window]   Figure 3. In situ detection of ROS in aortic sections. DCFDA was applied and images obtained by confocal microscopy. For all sections, lumen is to the right of the vessel wall. A, Representative cross section from control aorta. B and C, Cross sections from iron-loaded aorta, with arrow in C denoting intimal staining. Sections from iron-loaded animals were preincubated with catalase (D, 350 U/mL) or MPG (E, 100 µmol/L) for 30 minutes before addition of DCFDA.

View this table: [in this window] [in a new window]   TABLE 3. Measures of Systemic Oxidative Stress

Vascular Reactivity and NO Production
To determine if the enhanced vascular production of ROS after iron loading was associated with endothelial dysfunction, vascular reactivity studies were performed. In response to the endothelium-independent agonist nitroglycerin, there was no significant difference in peak relaxation (-99.1±0.9% versus -99.3±1.2, P=NS) or ED₅₀ (-7.52±0.13 log [M] versus -7.81±0.06, P=NS) of aortic rings from iron-loaded mice versus control mice (Figure 4A), suggesting that iron did not adversely affect smooth muscle function. In contrast, in response to the endothelium-dependent agonist acetylcholine, aortic rings from iron-loaded mice had significantly impaired peak relaxation (-54.8±13.4% versus -93.2±0.1, P=0.05) and a shift in the ED₅₀ (-6.24±0.49 log [M] versus -7.33±0.03, P<0.01) compared with control vessels (Figure 4B), suggesting decreased NO bioavailability. Consistent with these results, urinary nitrate/nitrite levels were lower in iron-loaded mice (760±640 nmol NO/mg creatinine, n=6) than in control mice (1700±980, n=9, P=0.06).

View larger version (21K): [in this window] [in a new window]   Figure 4. Vasorelaxation of aortic rings in response to nitroglycerin (A) and acetylcholine (B) for iron-loaded (n=3) and control animals (n=2).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
We have examined the impact of chronic iron administration on the thrombotic response to arterial injury, vascular production of ROS, and endothelium-dependent vasoreactivity, three components of vascular function that play major roles in the pathogenesis of ischemic vascular disease. The principal finding of our study is that chronic iron administration markedly accelerates the thrombotic response to arterial injury. This effect was observed at a level of tissue iron overload comparable to that observed in human iron storage diseases (500 to 14 000 µg/g wet liver).⁵ This prothrombotic effect of iron may represent a mechanism by which iron overload could increase the risk of cardiovascular death and myocardial infarction, as suggested by several epidemiological studies,^6–8 independent of a potential effect on atherosclerotic burden.

We hypothesized that iron overload could promote thrombosis through direct effects on the coagulation system. TF is a transmembrane protein that is essential for initiation of coagulation. Although previous studies have shown that TF expression is acutely enhanced under conditions of oxidative stress in cultured cells,^29,20 we did not detect any difference in vascular TF activity between the iron-loaded and saline-treated animals. Taken together with the absence of effects on plasma clotting, a direct influence of iron loading on the coagulation cascade appears unlikely.

Because platelets play a crucial role in arterial thrombosis and the thrombi induced by photochemical arterial injury are platelet-rich,³⁰ we examined the effects of iron excess on platelet function. There was no apparent effect of chronic iron administration on ADP-induced platelet aggregation. These results contrast with previous studies demonstrating that a single dose of iron dextran acutely increases platelet aggregation in rats³¹ and that iron chelators inhibit platelet aggregation in vitro.¹⁹ Iron-loaded animals demonstrated a trend toward an increase in the urinary metabolite of thromboxane A₂, a potent platelet agonist, as well as a significant increase in the urinary metabolite of prostacyclin, a potent inhibitor of platelet function. These results suggest that the impact of iron overload on prostaglandin metabolism may be complex and involve pathways with opposing effects on platelet reactivity. Therefore, although our studies indicate that platelet-rich thrombus formation after arterial injury is enhanced in the setting of chronic iron overload, a net stimulatory or inhibitory effect of iron excess on platelet function in vivo was not observed. Additional studies are necessary to resolve this issue.

By catalyzing the formation of ROS, iron excess may be deleterious to vascular function. Our study provides the first direct evidence that iron overload increases ROS generation locally within the vessel wall. The enhanced DCFDA staining observed in the aortas of iron-loaded mice was nearly abolished by MPG and catalase, suggesting that iron increased vessel wall production of both OH· and H₂O₂. Enhanced vascular production of ROS, combined with increased systemic lipid peroxidation that was observed in our study and others,¹⁴ lends further support to the concept that iron excess can increase oxidative stress in vivo. A significant impairment in endothelium-dependent vasorelaxation was observed in iron-loaded mice, reflecting reduced NO bioavailability, and consistent with the association between enhanced oxidative stress and endothelial dysfunction.²¹ Previous reports have described adverse effects of iron on brachial reactivity acutely.^32,33 Our observation that chronic iron overload impairs endothelium-dependent vascular reactivity is corroborated by a recent report of an association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis.³⁴

To test this hypothesis that enhanced ROS production could contribute to accelerated thrombosis in iron-loaded animals, we administered the ROS scavenger DL-cysteine after initiating photochemical injury. Although under certain conditions, exogenous cysteine may paradoxically exert pro-oxidant effects,^35,36 a previous report suggests that DL-cysteine displays antioxidant properties when administered acutely after photochemical injury.³⁰ We found that DL-cysteine completely abrogated the effects of iron loading on thrombus formation, significantly prolonging the time to vessel occlusion. This suggests that iron may accelerate thrombosis in this model by a pro-oxidant mechanism. Future studies will be helpful in clarifying whether iron enhances thrombosis after redox-independent vascular injury.

In conclusion, chronic parenteral administration of iron dextran markedly accelerates the thrombotic response to carotid artery injury, increases systemic and vascular ROS production, and impairs endothelium-dependent vasorelaxation in mice. Although the relevance of these mouse studies to vascular disease and thrombosis in humans is unknown, these data suggest that iron overload may increase the propensity for ischemic vascular events by impairing vascular function and increasing thrombotic risk.

	Acknowledgments

 
This work was supported in part by the National Institutes of Health T32 Training Grant in Molecular and Cellular Cardiology (HL07853, Dr Day) and National Institutes of Health grant HL57346 (Dr Fay). We are grateful to John Younger for statistical analysis and editorial assistance, Gerald Abrams for histology interpretation, and Michael Im for technical assistance.

	Footnotes

 
We examined the effects of systemic iron loading on arterial thrombosis, oxidative stress, and vascular reactivity in mice. Mean time to occlusive thrombosis after carotid artery injury was shorter in iron-loaded mice (20.4±8.5 minutes) than in control mice (54.5±35.5 minutes, P=0.009). This prothrombotic effect of iron was abrogated by the administration of a reactive oxygen species scavenger. Iron loading also resulted in increased systemic and vascular reactive oxygen species production and impaired endothelium-dependent vasoreactivity. Iron-induced vascular dysfunction may contribute to the increased incidence of ischemic cardiovascular events that have been associated with chronic iron overload.

Received December 9, 2002; revision received February 24, 2003; accepted February 26, 2003.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Horwitz LD, Rosenthal EA. Iron-mediated cardiovascular injury. Vasc Med. 1999; 4: 93–99.[Abstract/Free Full Text]
   
2. Fairbanks VF. Hemochromatosis. population genetics. In: Barton JC, Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis, and Treatment. Cambridge, England: Cambridge University Press; 2000: 42–50.
   
3. Bulaj ZJ, Griffen LM, Jorde LB, et al. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med. 1996; 335: 1799–1805.[Abstract/Free Full Text]
   
4. de Valk B, Addicks MA, Gosriwatana I, et al. Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. Eur J Clin Invest. 2000; 30: 248–251.[CrossRef][Medline] [Order article via Infotrieve]
   
5. Edwards CQ. Hemochromatosis and other iron storage disorders. In: Lee GR, Blache D, Foerster J, et al, eds. Wintrobe’s Clinical Hematology. Philadelphia, Pa: Lea & Febiger; 1993: 872–884.
   
6. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation. 1992; 86: 803–811.[Abstract/Free Full Text]
   
7. Tuomainen T-P, Kontula K, Nyyssonen K, et al. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in Eastern Finland. Circulation. 1999; 100: 1274–1279.[Abstract/Free Full Text]
   
8. Roest M, van der Schouw YT, de Valk B, et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation. 1999; 100: 1268–1273.[Abstract/Free Full Text]
   
9. Smith C, Mitchinson MJ, Aruoma OI, et al. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 1992; 286: 901–905.[Medline] [Order article via Infotrieve]
   
10. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest. 1984; 74: 1890–1894.[Medline] [Order article via Infotrieve]
    
11. Kirk EA, Heinecke JW, LeBoeuf RC. Iron overload diminishes atherosclerosis in apoE-deficient mice. J Clin Invest. 2001; 107: 1545–1553.[Medline] [Order article via Infotrieve]
    
12. Lee T-S, Shiao M-S, Pan C-C, et al. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation. 1999; 99: 1222–1229.[Abstract/Free Full Text]
    
13. Araujo JA, Romano EL, Brito BE, et al. Iron overload augments the development of atherosclerotic lesions in rabbits. Art Thromb Vasc Biol. 1995; 15: 1172–1180.[Abstract/Free Full Text]
    
14. Dabbagh AJ, Shwaery GT, Keaney JF Jr, et al. Effect of iron overload and iron deficiency on atherosclerosis in the hypercholesterolemic rabbit. Arterioscler Thromb Vasc Biol. 1997; 17: 2638–2645.[Abstract/Free Full Text]
    
15. Danesh J, Appleby P. Coronary heart disease and iron status. Circulation. 1999; 99: 852–854.[Abstract/Free Full Text]
    
16. Sullivan JL. Iron and the genetics of cardiovascular disease. Circulation. 1999; 100: 1260–1263.[Free Full Text]
    
17. Aukrust P, Berge RK, Ueland T, et al. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol. 2001; 37: 485–491.[Abstract/Free Full Text]
    
18. Ambrosio G, Tritto I, Golino P. Reactive oxygen metabolites and arterial thrombosis. Cardiovasc Res. 1997; 34: 445–452.[Abstract/Free Full Text]
    
19. Praticò D, Pasin M, Barry OP, et al. Iron-dependent human platelet activation and hydroxyl radical formation: involvement of protein kinase C. Circulation. 1999; 99: 3118–3124.[Abstract/Free Full Text]
    
20. Penn MS, Cui M-Z, Winokur AL, et al. Smooth muscle cell surface tissue factor pathway activation by oxidized low-density lipoprotein requires cellular lipid peroxidation. Blood. 2000; 96: 3056–3063.[Abstract/Free Full Text]
    
21. Russo G, Leopold JA, Loscalzo J. Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis. Vasc Pharmacol. 2002; 38: 259–269.
    
22. Eitzman DT, Westrick RJ, Xu Z, et al. Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E–deficient mice. Arterioscler Thromb Vasc Biol. 2000; 20: 1831–1834.[Abstract/Free Full Text]
    
23. Singh R, Pan S, Mueske CS, et al. Role for tissue factor pathway in murine model of vascular remodeling. Circ Res. 2001; 89: 71–76.[Abstract/Free Full Text]
    
24. Kojda G, Laursen JB, Ramasamy S, et al. Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control. Cardiovasc Res. 1999; 42: 206–213.[Abstract/Free Full Text]
    
25. Ohba M, Shibanuma M, Kuroki T, et al. Production of hydrogen peroxide by transforming growth factor-beta 1 and its involvement in induction of egr-1 in mouse osteoblastic cells. J Cell Biol. 1994; 126: 1079–1088.[Abstract/Free Full Text]
    
26. Torrance JD, Bothwell TH. Tissue iron stores. In: Cook JD, ed. Methods in Hematology: Iron. New York, NY: Churchill Livingstone; 1980: 90–113.
    
27. Tanaga K, Bujo H, Inoue M, et al. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol. 2002; 22: 662–666.[Abstract/Free Full Text]
    
28. Morrow JD, Roberts LJ. Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol. 1994; 233: 163–174.[Medline] [Order article via Infotrieve]
    
29. Golino P, Ragni M, Cirillo P, et al. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med. 1996; 2: 35–40.[CrossRef][Medline] [Order article via Infotrieve]
    
30. Saniabadi AR, Umemura K, Matsumoto N, et al. Vessel wall injury and arterial thrombosis induced by a photochemical reaction. Thromb Haemost. 1995; 73: 868–872.[Medline] [Order article via Infotrieve]
    
31. Polette A, Blache D. Effect of vitamin E on acute iron load-potentiated aggregation, secretion, calcium uptake and thromboxane biosynthesis in rat platelets. Atherosclerosis. 1992; 96: 171–179.[CrossRef][Medline] [Order article via Infotrieve]
    
32. Duffy SJ, Biegelsen ES, Holbrook M, et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2001; 103: 2799–2804.[Abstract/Free Full Text]
    
33. Rooyakkers TM, Stroes ESG, Kooistra MP, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest. 2002; 32 (suppl 1): 9–16.
    
34. Gaenzer H, Marschang P, Sturm W, et al. Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol. 2002; 40: 2189–2194.[Abstract/Free Full Text]
    
35. Yang EY, Campbell A, Bondy SC. Configuration of thiols dictates their ability to promote iron-induced reactive oxygen species generation. Redox Report. 2000; 5: 371–375.[CrossRef][Medline] [Order article via Infotrieve]
    
36. Anderson ME, Meister A. Intracellular delivery of cysteine. Methods Enzymol. 1987; 143: 313–325.[Medline] [Order article via Infotrieve]
    

This article has been cited by other articles:

				S. Swaminathan, V. A. Fonseca, M. G. Alam, and S. V. Shah The Role of Iron in Diabetes and Its Complications Diabetes Care, July 1, 2007; 30(7): 1926 - 1933. [Full Text] [PDF]

				L. N Hanson, H. M Engelman, D L. Alekel, K. L Schalinske, M. L Kohut, and M. B Reddy Effects of soy isoflavones and phytate on homocysteine, C-reactive protein, and iron status in postmenopausal women. Am. J. Clinical Nutrition, October 1, 2006; 84(4): 774 - 780. [Abstract] [Full Text] [PDF]

				Y.-D. Tang and S. D. Katz Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options Circulation, May 23, 2006; 113(20): 2454 - 2461. [Full Text] [PDF]

				D. L. van der A, J. J.M. Marx, D. E. Grobbee, M. H. Kamphuis, N. A. Georgiou, J. H. van Kats-Renaud, W. Breuer, Z. I. Cabantchik, M. Roest, H. A.M. Voorbij, et al. Non-Transferrin-Bound Iron and Risk of Coronary Heart Disease in Postmenopausal Women Circulation, April 25, 2006; 113(16): 1942 - 1949. [Abstract] [Full Text] [PDF]

				H. Zheng, R. Cable, B. Spencer, N. Votto, and S. D. Katz Iron Stores and Vascular Function in Voluntary Blood Donors Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1577 - 1583. [Abstract] [Full Text] [PDF]

				J. Borawski, J. Gozdzikiewicz, P. Abramowicz, B. Naumnik, and M. Mysliwiec Endothelial Injury Markers With High-dose IntravenousIron Therapy in Renal Failure Clinical and Applied Thrombosis/Hemostasis, October 1, 2004; 10(4): 403 - 406. [Abstract] [PDF]

				G. Ramakrishna, T. W Rooke, and L. T Cooper Iron and peripheral arterial disease: revisiting the iron hypothesis in a different light Vascular Medicine, August 1, 2003; 8(3): 203 - 210. [Abstract] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 107/20/2601    most recent 01.CIR.0000066910.02844.D0v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Day, S. M. Articles by Fay, W. P. Search for Related Content PubMed PubMed Citation Articles by Day, S. M. Articles by Fay, W. P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYSTEINE IRON IRON DEXTRAN NITRIC OXIDE Related Collections Animal models of human disease Arterial thrombosis Oxidant stress